1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
5Werle-Lapostolle B,Bowden S,Locarnini S,et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.Gastroenterology,2004,126:1750-1758.
6Evans A,Riva A,Cooksley H,et al.Programmed death 1 expression during antiviral treatment of chronic hepatitis B:impact of hepatitis B e-antigen seroconversion.Hepatology,2008,48:759-769.
7Keeffe EB,Zeuzem S,Koff RS,et al.Report of an international workshop:roadmap for management of patients receiving oral therapy for chronic hepatitis B.Clin Gastroenterol Hepatol,2007,5:890-897.
10World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 dex. (Revised October 2000). WHO Web site. http://www. who. int/mediacentre/ factsheets/fs204/en/ in html.
5Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamividine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005, 352: 2682-2695.
6Kobayyashi M, Suzuki F, Akuta N, et al. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with larnivudine. J Med Virol, 2007, 79: 1472-1477.
7Kobayashi M, Suzuki F, Akuta N, et al. Loss of hepatitis B surface antigen from he serum of patients with chronic hep- atitis treated with lamivudine [ J ]. J Med Virol, 2007, 79(10) : 1472-1477.
